Gossamer Bio, Inc.

Gossamer Bio, Inc. announced the final tender results for its exchange offer of 5.00% Convertible Senior Notes due 2027. The company successfully exchanged $181,052,000 of the existing notes for new 7.50% Convertible Senior Secured First Lien Notes due 2030, common stock, and warrants, after amending the minimum tender condition to 90.5%. Following the offer, $18,948,000 in existing notes will remain outstanding. Stockholder proposals related to the exchange offer will be voted on at a special meeting on July 14, 2026.

Gossamer Bio, Inc. has filed a definitive proxy statement (DEF 14A) announcing a Special Meeting of Stockholders to be held virtually on July 14, 2026. The meeting will address several key proposals, including the approval of share issuances related to an exchange offer, an amendment to the company's incentive award plan, an increase in authorized shares, and a potential reverse stock split. The company recently completed the early settlement of its exchange offer for its 5.00% Convertible Senior Notes due 2027, issuing new convertible notes, common stock, and warrants. The Board of Directors recommends a vote in favor of all proposals.

Gossamer Bio, Inc. announced the early settlement of its exchange offer and consent solicitation for its 5.00% Convertible Senior Notes due 2027. The company accepted $181,052,000 in principal amount of existing notes, representing 90.526% of the outstanding amount, after amending the minimum tender condition. In exchange, Gossamer Bio issued $65,174,000 in new 7.50% Convertible Senior Secured First Lien Notes due 2030, along with 254,150,441 new common shares, 33,402,727 prefunded warrants, and 135,789,000 purchase warrants. The consent solicitation also successfully amended the existing note indenture, removing restrictive covenants.

Gossamer Bio, Inc. announced the extension of the early tender deadline for its exchange offer and consent solicitation regarding its 5.00% Convertible Senior Notes due 2027. The new deadline is June 2, 2026, with an expected early settlement date of June 4, 2026. As of June 1, 2026, $181,052,000 in existing convertible notes had been tendered, with a minimum condition of 98% of the aggregate principal amount required for the exchange offer. The offer involves exchanging existing notes for new 7.50% Convertible Senior Secured First Lien Notes due 2030, common stock, or prefunded warrants, and purchase warrants.

Gossamer Bio commenced an exchange offer and consent solicitation for its 5.00% Convertible Senior Notes due 2027, aiming to reduce outstanding convertible debt by $128 million to $72 million and extend maturity to 2030. The company also reported a Q1 2026 net loss of $46.7 million, with cash, cash equivalents, and marketable securities totaling $99.2 million as of March 31, 2026, expected to fund operations into Q1 2027. Additionally, Gossamer Bio announced positive PROSERA CT FRI substudy results for seralutinib in PAH and confirmed an in-person Pre-NDA Type B meeting with the FDA in mid-June, with an NDA submission expected in September 2026.

Gossamer Bio reported a net loss of $46.7 million for the first quarter of 2026, an increase from $36.6 million in the prior year, despite a 71.5% rise in revenue to $17.0 million. The company issued a "going concern" warning, stating that its existing cash and cash equivalents are not sufficient to fund operating plans for at least one year. To address this, Gossamer Bio commenced a workforce reduction of 73 individuals, representing approximately 46% of its staff, incurring $6.1 million in related charges.

Gossamer Bio, Inc. (GOSS) announced on April 8, 2026, that it received a written notice from Nasdaq's Listing Qualifications Department regarding non-compliance with the minimum bid price requirement. The company's common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, specifically from February 24, 2026, through April 7, 2026. This notice does not result in immediate delisting, as Gossamer Bio has a 180-calendar-day period, until October 5, 2026, to regain compliance. Failure to meet this deadline could lead to a potential transfer to the Nasdaq Capital Market and necessitate actions such as a reverse stock split to cure the deficiency.